Cardiac amyloidosis represents an infiltrative cardiomyopathy characterized by accumulation of amyloid fibrils within the myocardium.

Advances in multimodality imaging have facilitated earlier diagnosis and prompt initiation of disease modifying therapies.

Cardiac imaging will play a key role in tracking treatment response.

Research focused on improved precision may augment detection of changes earlier during treatment.

Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardial extracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiation of disease-modifying therapies. Furthermore, rapid advances in multimodality imaging have enriched understanding of the underlying pathogenesis, enhanced prognostication, and resulted in the development of imaging-based markers that reflect the amyloid burden, which is of increasing importance when assessing the response to treatment. Whereas conventional therapies have focused on reducing amyloid formation and subsequent stabilization of the cardiac disease process, novel agents are being developed to accelerate the immune-mediated removal of amyloid fibrils from the heart. In this context, the ability to track changes in the amyloid burden over time is of paramount importance. Although advanced imaging techniques have shown efficacy in tracking the treatment response, future research focused on improved precision through use of artificial intelligence may augment the detection of changes earlier in the course of treatment.

Cardiac amyloidosis

systemic light-chain amyloidosis

transthyretin amyloidosis

light-chain cardiac amyloidosis

transthyretin cardiac amyloidosis

cardiac magnetic resonance

late gadolinium enhancement

positron emission tomography

© 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.